RxDoctor Payments Data

Omolola Otubaga, NP

Psychiatric/Mental Health · Fayetteville, GANPI 1033595566

Payments from drug & device makers

$3,464in general payments, 2019–2025

Across 135 payments — averaging $25.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$630
  • Johnson & Johnson$612
  • Neuronetics, Inc.$557
  • Otsuka America Pharmaceutical, Inc.$354
  • Indivior Inc.$322
  • Supernus Pharmaceuticals, Inc.$256
  • plus $733 from 13 others

What the payments were for

  • Travel & lodging$2136%
  • Food & beverage$3,20492%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,464 in reported general payments places this provider in the 90th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$10,676
Medicare patients
14
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate15$153,772
BelsomraSuvorexant12$9,478
Trazodone Hcl36$1,030
Olanzapine14$534
Bupropion XlBupropion Hcl25$447
Sertraline Hcl41$440
Quetiapine Fumarate17$396
Lorazepam21$272
Hydroxyzine Pamoate14$247
Risperidone34$246
Mirtazapine13$245
Benztropine Mesylate15$225
Lamotrigine20$162
Lithium Carbonate20$152
Clonazepam21$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza$612$153,77215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Fayetteville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →